Expertise in
17
conditions

Sylvain Adam-Marchand

Tours, FR 
Expertise in
17
conditions
Tours, FR 

Overview

Sylvain Adam-Marchand practices practicing medicine in Tours, France.

Mr. Adam-Marchand is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Lung Transplant.

He is actively involved in clinical research, co-authoring 147 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Tours, France
Other Locations
Suresnes, France
Francois, 37032, France
Lyon, France
Creteil, France
Paris, France
Grenoble, France
Caen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial
Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Drug
Study Drug: Pirfenidone
Study Phase: Phase 4
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
View 4 Less Clinical Trials

146 Total Publications

Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.
Aspergillosis complicating idiopathic lung fibrosis: a multicentric series.
Journal: Respiratory medicine
Published: February 22, 2026

Frequently Asked Questions about Sylvain Adam-Marchand

Is Sylvain Adam-Marchand a top-rated expert for Acute Interstitial Pneumonia?

MediFind is an objective health platform that identifies experts based on real-world data. Sylvain Adam-Marchand is classified as an Elite expert for Acute Interstitial Pneumonia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sylvain Adam-Marchand participate in research or clinical trials?

Yes. Sylvain Adam-Marchand has published 146 articles and abstracts on conditions like Acute Interstitial Pneumonia. You can view a list of Sylvain Adam-Marchand's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Adam-Marchand's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 49 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile